Browse by category

Fasting completion rates during Ramadan are significantly influenced by the time elapsed since surgery, with patients who underwent laparoscopic sleeve gastrectomy (LSG) 12 months or more before Ramadan having the highest success rates, according to researchers from Benha University, Benha and Tanta University, Tanta, Egypt. In addition, prior fasting experiences positively impacted fasting completion rates. The study authors stated that fasting during Ramadan presents unique

Intraparietal gastric botulinum toxin-A injection (Botox) can lead to significant weight loss and may contribute to the development of effective, minimally-invasive approaches for the management of obesity, according to researchers from Turkey. However, they noted that further studies with larger sample sizes and longer follow-up periods are needed to confirm these findings. This study investigated the effects of intragastric botulinum toxin-A injection on weight loss and to

The first meta-analysis to analyse objective oesophageal function data comparing pre- and post- laparoscopic vertical sleeve gastrectomy (LVSG), has conclusively demonstrated the detrimental effect of LVSG on lower esophageal sphincter pressure (LESP) and DeMeester Score (DMS) post-surgery despite significant loss of BMI, researchers from the University of Southern Queensland, Toowoomba, Queensland, Australia. Research has shown that LVSG leads to anatomical changes at the es

Medtimo, a wholly owned subsidiary of Biorad Medisys Private Limited, has filed a patent infringement complaint in the US District Court of the District of Delaware against Allurion Technologies. Medtimo’s complaint claims Allurion's gastric balloon system infringes upon Medtimo's intellectual property. This definitive action follows Allurion’s recent unsuccessful challenge of Medtimo’s patent rights in the US Patent and Trademark Office (USPTO). The complaint alleges that Al

The first peer-reviewed study on the consecutive use of the Allurion’s Smart Capsule, a first of its kind, swallowable, procedure-less weight-loss device, has revealed the multi-centre, retrospective outcomes demonstrated that two consecutive treatments can achieve average total body weight loss of 22.1% (19.3 kg), results comparable to bariatric surgery and high-dose GLP-1 therapy. The Allurion Smart Capsule is designed to be swallowed during a brief outpatient visit, filled

Novo Nordisk has entered into a definitive agreement to acquire Akero Therapeutics, a publicly held clinical-stage company developing innovative treatments for patients with serious metabolic diseases marked by a high unmet medical need. Akero’s fibroblast growth factor 21 (FGF21) analogue efruxifermin (EFX) is a potentially best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH). EFX is currently in phase 3 development for the treatment of patient